Buy Pradaxa (Dabigatran)

Inside, regardless of the food intake time, drink a glass of water to facilitate the drug to the stomach, 1 or 2 times a day. The capsule should not be opened.

 

 

Adult use

 

Prevention of venous thromboembolias (VTE) in patients after orthopaedic operations:

The recommended dose is 220 mg once a day (2 caps. for 110 mg).

 

For patients with moderate renal dysfunction due to the risk of bleeding the recommended dose is 150 mg once a day (2 caps. 75 mg each).

 

VTE prophylaxis after knee joint endoprosthesis:

Pradaxa® should be used 1-4 hours after the operation with 1 capsule (110 mg) with subsequent dose increase to 2 caps. (220 mg) once a day for the following 10 days.

If hemostasis is not achieved, treatment should be postponed.

If treatment has not started on the day of surgery, the therapy should be started with 2 caps. (220 mg) once a day.

 

VTE prophylaxis after hip arthroplasty:

Pradaxa® should be used 1-4 hours after the operation with 1 capsule (110 mg) with subsequent dose increase up to 2 caps. (220 mg) once a day for the following 28-35 days.

If hemostasis is not achieved, treatment should be postponed.

If treatment has not started on the day of surgery, the therapy should be started with 2 caps. (220 mg) once a day.

 

Prevention of stroke, systemic thromboembolism and cardiovascular death in patients with atrial fibrillation:

It is recommended to use Pradaxa® in a daily dose of 300 mg (1 capsule, 150 mg 2 times a day). The therapy should continue for life.

 

Treatment of acute DVT and/or PE:

It is recommended to use Pradaxa® in a daily dose of 300 mg (1 capsule, 150 mg 2 times a day) after parenteral anticoagulant treatment performed for at least 5 days. The therapy should continue for up to 6 months.

 

Prevention of acute DVT and/or PE:

It is recommended to use Pradaxa® in a daily dose of 300 mg (1 capsule, 150 mg 2 times a day). The therapy may continue for life, depending on individual risk factors.

 

 

• hypersensitivity to dabigatrane, dabigatrane etexylate or any of the auxiliary substances;

 

• severe renal failure (Cl creatinine <30 ml/min);

 

• active clinically significant bleeding, hemorrhagic diathesis, spontaneous or pharmacologically induced hemostasis disorder;

 

• organ damage due to clinically significant bleeding, including hemorrhagic stroke for 6 months before therapy;

 

• significant risk of major bleeding from an existing or recent gastrointestinal ulcer, presence of malignant lesions with a high risk of bleeding, recent brain or spinal cord injury, recent brain or spinal cord surgery or ophthalmic surgery, recent intracranial hemorrhage, presence or suspicion of oesophageal varicose veins, congenital arteriovenous defects, vascular aneurysms or large intravertebral or cerebral vascular disorders;

 

 

• simultaneous administration of any other anticoagulants, including non-fractionated heparin, low-molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, apixaban, etc.). ), except in case of treatment switch from or to Pradaxa® or in case of application of unfractionated heparin in doses necessary for maintenance of central venous or arterial catheter;

 

• simultaneous administration of ketoconazole for systemic use, cyclosporine, itraconazole, tacrolimus and dronedarone;

 

• liver dysfunction and liver diseases that may affect survivability;

 

• resence of a prosthetic heart valve;

 

• age under 18 (no clinical data available).

 

 

Careful:

 

Conditions that increase the risk of bleeding:

 

• age 75 years and over;

 

• moderate decrease of kidney function (creatinine Cl - 30-50 ml/min);

 

• simultaneous use of P-gp inhibitors;

 

• body weight less than 50 kg;

 

• simultaneous use of acetylsalicylic acid, LDPA, clopidogrela, SIO and other drugs, the use of which may disturb hemostasis;

 

• congenital or acquired clotting system diseases;

 

• thrombocytopenia or platelet function defects;

 

• recent biopsy or extensive trauma;

 

• bacterial endocarditis;

 

• esophagitis, gastritis or gastroesophageal reflux disease.

 

 

• any other anticoagulants, including non-fractionated heparin, low-molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, apixaban, etc.). );

 

• ketoconazole; 

 

• cyclosporine; 

 

• itraconazole; 

 

• tacrolimus;

 

• dronedarone;

 

 

Be careful in case of simultaneous use of:

 

• acetylsalicylic acid

 

• LDPA 

 

• clopidogrela 

 

• SIO

 

• and other drugs, the use of which may disturb hemostasis

Symptoms:

 

overdose of Pradaxa® may be accompanied by hemorrhagic complications.

 

 

Treatment:

 

In case of bleeding, the use of the drug is stopped. The symptomatic treatment is indicated. There is no specific antidote.

 

For situations where rapid elimination of activity is required, there is a specific antidote of dabigatran (idarucizumab), which is an antagonist in relation to the pharmacodynamic action of Pradaxa®.

Bleeding of any localization is possible. Extensive bleeding is rare. The development of undesirable reactions was similar to those of sodium enoxaparin.

 

Hematopoietic system: anemia, thrombocytopenia.

 

Blood coagulation system: hematoma, wound bleeding, nosebleed, gastrointestinal bleeding, rectal bleeding, hemorrhoid bleeding, skin hemorrhagic syndrome, hemarthrosis, hematuria.

 

Digestive system: liver function disorders, increased liver transaminases activity, hyperbilirubinemia.

 

Laboratory indicators: decrease of hemoglobin and hematocrit levels.

 

Local reactions: bleeding from the injection site.

 

Complications related to procedures and surgical interventions:

hemorrhage from the wound, hematoma after procedures, postoperative anemia, post-traumatic hematoma, hemorrhage after procedures, bleeding from the incision site, drainage after procedures, wound drainage.

 

 

The frequency of observed undesirable reactions when taking dabigatran etexylate did not exceed the range of undesirable reactions developing with sodium enoxaparin.

Pradaxa is an active substance, this medicinal product is a predecessor of dabigatran (a substance inhibiting thrombin). After ingestion and absorption in the gastro-intestinal tract, and then under the influence of liver enzymes, dabigatran etexylate turns into dabigatran identical to that present in the human body. This substance prevents the production of thrombin, which turns into fibrin (the main clot substance), thus preventing the formation of blood clots.

Active ingredient:

 

dabigatran etexylate mesilate - 86,48/126,83/172,95 mg,

corresponds to dabigatran etexylate - 75/110/150 mg.

 

 

Auxiliary substances:

 

capsule contents: Acacia gum - 4,43/6,5/8,86 mg; tartaric acid, coarse-grained - 22,14/32,48/44,28 mg; tartaric acid, powder - 29,52/43,3/59,05 mg; tartaric acid, crystalline - 36,9/54,12/73,81 mg; hypromellose - 2.23/3.27/4.46 mg; dimethicone - 0.04/0.06/0.08 mg; talcum powder - 17.16/25.16/34.31 mg; hyprolose (hydroxypropylcellulose) - 17.3/25.37/34.59 mg.

 

capsule shell: hypromellose capsule (HPMC) with an overprint in black ink.

 

HPMC capsule composition: Carrageenan (E407) - 0.2/0.22/0.285 mg; potassium chloride - 0.27/0.31/0.4 mg; titanium dioxide (E171) - 3.6/4.2/5.4 mg; indigo carmine (E132) - 0.036/0.042/ 0.054 mg; dye "Sunset" yellow (E110) - 0.002/0.003/0.004 mg; hypromellose (hydroxypropyl methylcellulose) - 52.9/61.71/79.35 mg, purified water - 3/3.5/4.5 mg.

 

black ink, %, wt.: shellac - 24-27%; butanol - 1-3%; isopropanol - 1-3%; iron dye black oxide (E172) - 24-28%; purified water - 15-18%; propylene glycol - 3-7%; ethanol - 23-26%; ammonia water - 1-2%; potassium hydroxide - 0,05-0,1%.

• lack of direct analogues with similar composition and mechanism of action; 

 

• presence of active and auxiliary components, the effectiveness of which has been proved laboratory and practical; 

 

• the possibility of taking as a prophylactic drug, which ensures the prevention of pathological conditions, rather than their subsequent treatment;

 

• Low price compared to analogues.

At temperatures not exceeding 25 °C, in the original packaging.

 

Keep out of the reach of children.

 

Shelf life: 3 years.

Do not use after the expiration date indicated on the package.

There is no prescription required!

You can legally buy Pradaxa on our website without prescription!

You can buy Pradaxa from our website absolutely legally.

 

Delivery is carried out to all countries in the world, which do not have an official ban on receiving and sending mail (mainly island countries).

 

We guarantee that you will receive your parcel with Pradaxa without any problems at customs (we have our own delivery channels to countries with strict customs).

 

We guarantee a refund if your package has not been delivered to you for any reason, according to PayPal protection policy.

 

Due to Quarantine, delivery time may increase slightly, but still delivery remains within reasonable limits and does not exceed the delivery time during Christmas sales.

Pradaxa Full Description (PDF)